Covaxin phase 3 trial to begin on November 20, Minister Anil Vij offers to be 1st volunteer

Published On 2020-11-19 06:49 GMT   |   Update On 2020-11-19 06:50 GMT

Chandigarh: Haryana Health Minister Anil Vij on Wednesday said the third phase of trial of Covaxin, a potential vaccine against COVID-19, will begin in the state on November 20 and offered to be the first volunteer to get vaccinated.Covaxin is being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).Last month, the vaccine maker had...

Login or Register to read the full article

Chandigarh: Haryana Health Minister Anil Vij on Wednesday said the third phase of trial of Covaxin, a potential vaccine against COVID-19, will begin in the state on November 20 and offered to be the first volunteer to get vaccinated.

Covaxin is being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Last month, the vaccine maker had said it had successfully completed interim analysis of Phase 1 and 2 trials and is initiating Phase 3 trials.

"Trial for third phase of Covaxin, a coronavirus vaccine product of Bharat Biotech, to start in Haryana on 20th November. I have offered myself as the first volunteer to get vaccinated," Vij said in a tweet.

Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR.

Read also: Govt scientist says India-made COVID-19 vaccine could be launched by February

It is the largest clinical trial conducted for a COVID-19 vaccine in India.

This is India''s first Phase 3 efficacy study for a COVID-19 vaccine, and the largest Phase 3 efficacy trial ever conducted.

The human trial of Covaxin had begun at Rohtak''s Post Graduate Institute of Medical Sciences in July, Vij had said earlier.

Read also: Bharat Biotech Covaxin enters phase 3 trials



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News